Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated nebulised gene therapy in cystic fibrosis
ISRCTN71164341Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Mar 2012
- Modality
- Gene Therapies
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing pGM169/GL67A with Placebo (2 arms). Primary endpoint: Relative change in percent predicted FEV1 after 12 doses. Started Mar 2012; status: completed.
02
Drugs
pGM169 + GL67A
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ISRCTN71164341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71164341.